Influence of G-CSF and EPO on Associative Learning and Motor Skills
Primary Purpose
Chronic Stroke, Amyotrophic Lateral Sclerosis
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
granulocyte - colony stimulating factor (G-CSF)
erythropoetin (EPO)
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Stroke
Eligibility Criteria
Inclusion Criteria: Diagnosis of chronic stroke or amyotrophic lateral sclerosis Exclusion Criteria: leucocytes > 10000/µl hematocrit > 48% thrombocytes < 150000/µl severe rheumatoid arthritis severe infection severe liver or renal failure severe arterial hypertension recurrent thromboembolic events severe coronary heart disease myocardial infarction malignant tumor leukemia peripheral arterial occlusion disease
Sites / Locations
- Department of neurology, University Hospital of Muenster
Outcomes
Primary Outcome Measures
Learning success in a word learning model
Response time in motor function tests
Secondary Outcome Measures
Response time in a word learning model
Total time and number of keystrokes in motor function tests
Full Information
NCT ID
NCT00298597
First Posted
March 1, 2006
Last Updated
April 22, 2009
Sponsor
University Hospital Muenster
1. Study Identification
Unique Protocol Identification Number
NCT00298597
Brief Title
Influence of G-CSF and EPO on Associative Learning and Motor Skills
Official Title
Influence of G-CSF and EPO on Associative Learning and Motor Skills
Study Type
Interventional
2. Study Status
Record Verification Date
April 2007
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
University Hospital Muenster
4. Oversight
5. Study Description
Brief Summary
In the study we want to prove whether the subcutaneous application of granulocyte-stimulating factor (G-CSF) and erythropoetin (EPO) influence associative learning and/or motor skills of patients, who suffer from chronic stroke or amyotrophic lateral sclerosis. The study hypothesis is that G-CSF and EPO improve associative learning and/or motor skills.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Stroke, Amyotrophic Lateral Sclerosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
180 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
granulocyte - colony stimulating factor (G-CSF)
Intervention Type
Drug
Intervention Name(s)
erythropoetin (EPO)
Primary Outcome Measure Information:
Title
Learning success in a word learning model
Title
Response time in motor function tests
Secondary Outcome Measure Information:
Title
Response time in a word learning model
Title
Total time and number of keystrokes in motor function tests
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of chronic stroke or amyotrophic lateral sclerosis
Exclusion Criteria:
leucocytes > 10000/µl
hematocrit > 48%
thrombocytes < 150000/µl
severe rheumatoid arthritis
severe infection
severe liver or renal failure
severe arterial hypertension
recurrent thromboembolic events
severe coronary heart disease
myocardial infarction
malignant tumor
leukemia
peripheral arterial occlusion disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wolf Rüdiger Schäbitz, MD
Organizational Affiliation
Department of Neurology, University Hospital of Muenster, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of neurology, University Hospital of Muenster
City
Muenster
State/Province
Nordrhein-Westfalen
ZIP/Postal Code
D-48149
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
15236398
Citation
Knecht S, Breitenstein C, Bushuven S, Wailke S, Kamping S, Floel A, Zwitserlood P, Ringelstein EB. Levodopa: faster and better word learning in normal humans. Ann Neurol. 2004 Jul;56(1):20-6. doi: 10.1002/ana.20125.
Results Reference
background
PubMed Identifier
16258290
Citation
Schneider A, Kuhn HG, Schabitz WR. A role for G-CSF (granulocyte-colony stimulating factor) in the central nervous system. Cell Cycle. 2005 Dec;4(12):1753-7. doi: 10.4161/cc.4.12.2213. Epub 2005 Dec 27.
Results Reference
background
PubMed Identifier
16007267
Citation
Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, Laage R, Aronowski J, Maurer MH, Gassler N, Mier W, Hasselblatt M, Kollmar R, Schwab S, Sommer C, Bach A, Kuhn HG, Schabitz WR. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005 Aug;115(8):2083-98. doi: 10.1172/JCI23559. Epub 2005 Jul 7.
Results Reference
background
PubMed Identifier
21625426
Citation
Floel A, Warnecke T, Duning T, Lating Y, Uhlenbrock J, Schneider A, Vogt G, Laage R, Koch W, Knecht S, Schabitz WR. Granulocyte-colony stimulating factor (G-CSF) in stroke patients with concomitant vascular disease--a randomized controlled trial. PLoS One. 2011;6(5):e19767. doi: 10.1371/journal.pone.0019767. Epub 2011 May 23.
Results Reference
derived
PubMed Identifier
21423758
Citation
Duning T, Schiffbauer H, Warnecke T, Mohammadi S, Floel A, Kolpatzik K, Kugel H, Schneider A, Knecht S, Deppe M, Schabitz WR. G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial. PLoS One. 2011 Mar 14;6(3):e17770. doi: 10.1371/journal.pone.0017770.
Results Reference
derived
Learn more about this trial
Influence of G-CSF and EPO on Associative Learning and Motor Skills
We'll reach out to this number within 24 hrs